Stratified/risk-based screening for colorectal cancer in the UK: an overview.

IF 0.3 Q3 ONCOLOGY
Colorectal Cancer Pub Date : 2025-05-20 eCollection Date: 2025-01-01 DOI:10.1080/1758194X.2025.2501851
Susanne Maxwell, David Weller, Becky Dennison, Lily Taylor, Hannah Miles, Joanne Cairns, Christian Von Wagner, Jazzine Smith, Juliet Usher-Smith
{"title":"Stratified/risk-based screening for colorectal cancer in the UK: an overview.","authors":"Susanne Maxwell, David Weller, Becky Dennison, Lily Taylor, Hannah Miles, Joanne Cairns, Christian Von Wagner, Jazzine Smith, Juliet Usher-Smith","doi":"10.1080/1758194X.2025.2501851","DOIUrl":null,"url":null,"abstract":"<p><p>While colorectal cancer screening is well-established in the UK, at present, it uses a 'one-size fits-all' approach - that is, individual risk is not considered when determining screening regimens (except for some specific conditions such as Lynch syndrome). Stratified screening offers the prospect of directing more intensive screening toward those at higher risk - with a corresponding reduction of screening intensity among lower-risk individuals. Two key opportunities for stratifying colorectal cancer screening are (1) making better use of an individual's quantitative fecal hemoglobin result rather than the current approach of deeming tests to be positive over an arbitrary threshold and (2) gathering information on lifestyle, family history, genetics and other factors to establish risk of colorectal cancer - and using this information to tailor screening regimens. While there is encouraging evidence from modeling studies demonstrating reduced colonoscopy requirements and increased positive prediction of colorectal cancer when incorporating risk assessments within screening, we need 'real world' evidence on stratified screening to establish whether it is effective, improves screening outcomes and is acceptable to the public. We also need to know the impact these changes would have on existing screening programs, and how programs might adapt their organizational and IT processes.</p>","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"14 1","pages":"2501851"},"PeriodicalIF":0.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/1758194X.2025.2501851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

While colorectal cancer screening is well-established in the UK, at present, it uses a 'one-size fits-all' approach - that is, individual risk is not considered when determining screening regimens (except for some specific conditions such as Lynch syndrome). Stratified screening offers the prospect of directing more intensive screening toward those at higher risk - with a corresponding reduction of screening intensity among lower-risk individuals. Two key opportunities for stratifying colorectal cancer screening are (1) making better use of an individual's quantitative fecal hemoglobin result rather than the current approach of deeming tests to be positive over an arbitrary threshold and (2) gathering information on lifestyle, family history, genetics and other factors to establish risk of colorectal cancer - and using this information to tailor screening regimens. While there is encouraging evidence from modeling studies demonstrating reduced colonoscopy requirements and increased positive prediction of colorectal cancer when incorporating risk assessments within screening, we need 'real world' evidence on stratified screening to establish whether it is effective, improves screening outcomes and is acceptable to the public. We also need to know the impact these changes would have on existing screening programs, and how programs might adapt their organizational and IT processes.

英国结直肠癌分层/基于风险的筛查:综述
虽然结直肠癌筛查在英国已经很成熟,但目前,它采用的是一种“一刀切”的方法——也就是说,在确定筛查方案时,不考虑个人风险(除了一些特定的情况,如林奇综合征)。分层筛查提供了对高风险人群进行更密集筛查的前景,同时相应地降低了对低风险人群的筛查强度。对结直肠癌筛查进行分层的两个关键机会是:(1)更好地利用个人的定量粪便血红蛋白结果,而不是目前认为测试结果超过任意阈值呈阳性的方法;(2)收集生活方式、家族史、遗传和其他因素的信息,以确定结直肠癌的风险,并利用这些信息来定制筛查方案。虽然模型研究中有令人鼓舞的证据表明,在筛查中纳入风险评估时,结肠镜检查的要求降低了,结直肠癌的阳性预测增加了,但我们需要“真实世界”的证据来确定分层筛查是否有效,是否改善了筛查结果,是否为公众所接受。我们还需要知道这些变化对现有筛选程序的影响,以及程序如何调整其组织和IT过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Colorectal Cancer
Colorectal Cancer ONCOLOGY-
自引率
0.00%
发文量
0
期刊介绍: Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信